nach oben

Reactions Weekly

Erschienen in:

01.08.2019 | Case report

Atezolizumab/ipilimumab/pembrolizumab

Facial paralysis: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective study of 364 patients, two patients [ages and sexes not stated] were described; one patient developed facial paralysis during treatment with ipilimumab and pembrolizumab for metastatic melanoma while one patient developed facial paralysis during treatment with atezolizumab for metastatic bladder cancer [routes, dosages, duration of treatments to reactions onsets and outcomes not stated]. …

Yuen C, et al. Facial palsy induced by cancer immunotherapy: A single center retrospective study. Neuro-Oncology 20 (Suppl. 6): vi198 abstr. NCMP-23, Nov 2018. Available from: URL: http://doi.org/10.1093/neuonc/noy148.822 [abstract] -USA

Titel: Atezolizumab/ipilimumab/pembrolizumab
Facial paralysis: 2 case reports
Publikationsdatum: 01.08.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-65819-x

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Atezolizumab/ipilimumab/pembrolizumab

Facial paralysis: 2 case reports

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Carboplatin

Chlorphenamine

Doxorubicin

Azacitidine

Antineoplastics

Ipilimumab/nivolumab